RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector Perform
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams downgraded Sage Therapeutics (NASDAQ: SAGE) from Outperform to Sector Perform with a price target of $25.00 (from $71.00).
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $36.10 yesterday.
You May Also Be Interested In
- Deutsche Bank Downgrades Apogee Therapeutics Inc (APGE) to Hold
- HDFC Asset Management Co Ltd (HDFCAMC:IN) PT Raised to INR3,250 at JPMorgan
- Southern Co. (SO) PT Lowered to $99 at Jefferies
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
